Avalo Therapeutics (NASDAQ:AVTX) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Avalo Therapeutics to “Sell” from “Hold,” although the broader analyst consensus remains “Moderate Buy,” with 13 Buy ratings and one Sell rating and a $45.10 average price target.
• Avalo shares opened at $18.32, versus a 12-month range of $8.29 to $24.27. The company reported quarterly EPS of $(0.83), missing the consensus estimate of $(0.58), and analysts expect a full-year loss of $2.58 per share.
• Institutional investors own 87.06% of the stock, with several hedge funds increasing their positions, while an insider sold 1,450 shares under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Several other brokerages also recently weighed in on AVTX. Weiss Ratings downgraded Avalo Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. Piper Sandler reaffirmed an "overweight" rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. BTIG Research reissued a "buy" rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Cantor Fitzgerald restated an "overweight" rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Finally, Bank of America initiated coverage on shares of Avalo Therapeutics in a research note on Friday, June 12th. They issued a "buy" rating and a $35.00 target price for the company. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Avalo Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.10.

Avalo Therapeutics Price Performance

Shares of Avalo Therapeutics stock opened at $18.32 on Friday. The stock has a market capitalization of $969.13 million, a price-to-earnings ratio of -4.19 and a beta of 0.80. The firm's fifty day simple moving average is $17.26 and its 200-day simple moving average is $16.29. Avalo Therapeutics has a 12 month low of $8.29 and a 12 month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.25). Analysts anticipate that Avalo Therapeutics will post -2.58 earnings per share for the current year.

Insider Buying and Selling at Avalo Therapeutics

In related news, insider Mittie Doyle sold 1,450 shares of the company's stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider owned 51,776 shares of the company's stock, valued at $931,968. This represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Orbimed Advisors LLC lifted its stake in shares of Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company's stock valued at $17,150,000 after purchasing an additional 382,300 shares during the period. Affinity Asset Advisors LLC boosted its stake in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company's stock worth $20,019,000 after acquiring an additional 289,786 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company's stock worth $15,697,000 after acquiring an additional 240,000 shares during the period. Caligan Partners LP grew its holdings in Avalo Therapeutics by 5.8% in the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company's stock valued at $16,009,000 after purchasing an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics during the third quarter worth $10,390,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source